The Continuing Role of PSA in the Detection and Management of Prostate Cancer

Partin, 1990, Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia, J Urol, 143, 747, 10.1016/S0022-5347(17)40079-6 Nadler, 1995, Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels, J Urol, 154, 407, 10.1016/S0022-5347(01)67064-2 Eastham, 2003, Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations, JAMA, 289, 2695, 10.1001/jama.289.20.2695 Yan, 2001, Intraindividual variation of prostate specific antigen measurement and implications for early detection of prostate carcinoma, Cancer, 92, 776, 10.1002/1097-0142(20010815)92:4<776::AID-CNCR1382>3.0.CO;2-E Raaijmakers, 2004, Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam, Urology, 63, 316, 10.1016/j.urology.2003.09.028 Thompson, 2004, Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0ng per milliliter, N Engl J Med, 350, 2239, 10.1056/NEJMoa031918 Thompson, 2005, Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0ng/ml or lower, JAMA, 294, 66, 10.1001/jama.294.1.66 NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer Early Detection V.I.2006. Available at www.nccn.org. Accessed 22 November 2006. Catalona, 2006, Making prostate-specific antigen testing more effective, Urol Oncol, 24, 177, 10.1016/j.urolonc.2005.09.001 Aus G, Abbou CC, Bolla M, et al. European Association of Urology Guidelines on Prostate Cancer. Available at http://wwwurowebnl/files/uploaded_files/2005Prostate%20Cancer.pdf. Accessed 19 December 2005. Stamey, 2004, The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?, J Urol, 172, 1297, 10.1097/01.ju.0000139993.51181.5d Catalona, 2005, The PSA era is not over for prostate cancer, Eur Urol, 48, 541, 10.1016/j.eururo.2005.07.014 Catalona, 2005, Serum PSA correlates more strongly with the percentage of prostate cancer and cancer volume than with prostate size, J Urol, 173, 257, 10.1016/S0022-5347(18)35105-X Roddam, 2005, Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10ng/ml: systematic review and meta-analysis, Eur Urol, 48, 386, 10.1016/j.eururo.2005.04.015 Carter, 1992, Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease, JAMA, 267, 2215, 10.1001/jama.267.16.2215 Fang, 2002, PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0ng/ml, Urology, 59, 889, 10.1016/S0090-4295(02)01646-1 Berger, 2005, Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk, J Urol, 173, 402, 10.1016/S0022-5347(18)35617-9 Schröder, 2006, Does PSA velocity predict prostate cancer in pre-screened populations?, Eur Urol, 49, 460, 10.1016/j.eururo.2005.12.026 Perrin, 2006, PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence, Eur Urol, 49, 418, 10.1016/j.eururo.2005.12.028 Catalona, 1994, Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves, J Urol, 152, 2031, 10.1016/S0022-5347(17)32299-1 Catalona, 2004, Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4ng/ml prostate specific antigen, J Urol, 171, 2239, 10.1097/01.ju.0000127737.94221.3e Becker, 2000, Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum, J Urol, 163, 311, 10.1016/S0022-5347(05)68044-5 Haese, 2003, Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies, J Urol, 170, 2269, 10.1097/01.ju.0000095794.04551.0c Mikolajczyk, 2003, Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer, Keio J Med, 52, 86, 10.2302/kjm.52.86 Becker, 2003, Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer, J Urol, 170, 1169, 10.1097/01.ju.0000086640.19892.0b Aslan, 2005, The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer, Int Urol Nephrol, 37, 511, 10.1007/s11255-005-0921-x Vaisanen, 2006, Free and total human glandular kallikrein 2 in patients with prostate cancer, Urology, 68, 219, 10.1016/j.urology.2006.01.075 Stephan, 2006, Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer, Int J Urol, 13, 238, 10.1111/j.1442-2042.2006.01276.x Raaijmakers, 2004, Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness, J Urol, 171, 2245, 10.1097/01.ju.0000127731.56103.50 Shariat, 2006, Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10ng/ml, Eur Urol, 49, 293, 10.1016/j.eururo.2005.10.027 Carter, 2005, PSA velocity and risk of prostate cancer death in the Baltimore Longitudinal Study of Aging, J Urol, 173, 257, 10.1016/S0022-5347(18)35107-3 D’Amico, 2004, Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy, N Engl J Med, 351, 125, 10.1056/NEJMoa032975 D’Amico, 2005, Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy, JAMA, 294, 440, 10.1001/jama.294.4.440 Klotz, 2005, Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer, Eur Urol, 47, 16, 10.1016/j.eururo.2004.09.010 Klotz, 2005, Active surveillance for prostate cancer: for whom?, J Clin Oncol, 23, 8165, 10.1200/JCO.2005.03.3134 Sengupta, 2005, Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy, J Urol, 174, 2191, 10.1097/01.ju.0000181209.37013.99 Gillatt, 2007, Eur Urol Suppl, 6, 325, 10.1016/j.eursup.2006.11.001 Brett, 2005, PSA testing for prostate cancer: an online survey of the views and reported practice of general practitioners in the UK, BMC Fam Pract, 6, 24, 10.1186/1471-2296-6-24 Grubb, 2005, Results of compliance with prostate cancer screening guidelines, J Urol, 174, 668, 10.1097/01.ju.0000165149.66186.23 Moul, 2003, Population screening for prostate cancer and emerging concepts for young men, Clin Prostate Cancer, 2, 87, 10.3816/CGC.2003.n.015 Whittemore, 2005, Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of black and white Americans, J Urol, 174, 872, 10.1097/01.ju.0000169262.18000.8a Yanke, 2005, Validation of a nomogram for predicting positive repeat biopsy for prostate cancer, J Urol, 173, 421, 10.1097/01.ju.0000150522.82760.00